Skip to main content

Table 1 Characteristics of EGC patients in the model development and validation cohorts

From: A novel DNA methylation signature associated with lymph node metastasis status in early gastric cancer

Characteristics

Model development cohort

Validation cohort

Training set, n = 151, (%)

Test set, n = 151, (%)

Validation set, n = 130, (%)

Age (years)

 < 60

85 (56.3)

78 (51.7)

76 (58.5)

 ≥ 60

66 (43.7)

73 (48.3)

54 (41.5)

Gender

Male

88 (58.3)

93 (61.6)

81 (62.3)

Female

63 (41.7)

58 (38.4)

49 (37.7)

Tumor location

Upper

18 (11.9)

21 (13.9)

21 (16.2)

Middle

21 (13.9)

29 (19.2)

26 (20.0)

Low

112 (74.2)

101 (66.9)

83 (63.8)

Tumor size (mm)

 ≤ 20

86 (56.9)

91 (60.3)

67 (51.5)

 > 20

65 (43.1)

60 (39.7)

63 (48.5)

Differentiation

Differentiated

40 (26.5)

51 (33.8)

43 (33.1)

Undifferentiated

111 (73.5)

100 (66.2)

87 (66.9)

Invasional depth

Mucosa

67 (44.4)

77 (51.0)

46 (35.4)

Submucosa

84 (55.6)

74 (49.0)

84 (64.6)

LVI

Presence

19 (12.6)

19 (12.6)

18 (13.8)

Absence

132 (87.4)

132 (87.4)

112 (86.2)

Ulceration

Presence

52 (34.4)

56 (37.1)

36 (27.7)

Absence

99 (65.6)

95 (62.9)

94 (72.3)

LNM

LNM+

36 (23.8)

36 (23.8)

32 (24.6)

LNM−

115 (76.2)

115 (76.2)

98 (75.4)

  1. LNM, lymph node metastasis; LNM+, samples of EGC patients with positive lymph node metastasis; LNM−, samples of EGC patients without lymph node metastasis; and LVI, lymphovascular invasion